Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Cost of Revenue: 2020-2025

Historic Cost of Revenue for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $1.4 million.

  • Insight Molecular Diagnostics' Cost of Revenue rose 32.89% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 58.06%. This contributed to the annual value of $3.9 million for FY2024, which is 41.11% up from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Cost of Revenue stood at $1.4 million, which was down 5.07% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' Cost of Revenue ranged from a high of $3.3 million in Q4 2021 and a low of $183,000 during Q2 2022.
  • Moreover, its 3-year median value for Cost of Revenue was $853,000 (2024), whereas its average is $981,000.
  • In the last 5 years, Insight Molecular Diagnostics' Cost of Revenue slumped by 93.15% in 2022 and then spiked by 339.89% in 2023.
  • Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Cost of Revenue stood at $3.3 million in 2021, then crashed by 89.91% to $334,000 in 2022, then surged by 74.25% to $582,000 in 2023, then soared by 106.53% to $1.2 million in 2024, then spiked by 32.89% to $1.4 million in 2025.
  • Its Cost of Revenue was $1.4 million in Q3 2025, compared to $1.5 million in Q2 2025 and $1.2 million in Q1 2025.